Table 1.
Correlations between the clinicopathological features and the anaplastic lymphoma kinase fusion gene in 200 patients with advanced non-small cell lung cancer
| Features | Total | EML4-ALK | P-value† | ||
|---|---|---|---|---|---|
| Positive | Negative | UN | |||
| n(%) | 200 (100) | 56 (28.0) | 122 (61.0) | 22 (11.0) | |
| Age (year) | |||||
| Median | 53 | 48 | 55 | 53 | <0.001 |
| Range | 25–76 | 25–74 | 27–76 | 26–60 | |
| Gender n(%) | |||||
| Male | 90 (45.0) | 20 (35.7) | 58 (47.5) | 12 (54.5) | 0.140 |
| Female | 110 (55.0) | 36 (64.3) | 64 (52.5) | 10 (45.5) | |
| Smoking status n(%) | |||||
| Never/light-smoking | 162 (81.0) | 49 (87.5) | 94 (77.0) | 19 (86.4) | 0.103 |
| Smoking | 38 (19.0) | 7 (12.5) | 28 (23.0) | 3 (13.6) | |
| Pathology n(%) | |||||
| Adenocarcinoma | 183 (91.5) | 52 (92.8) | 109 (89.3) | 22 (100) | 0.438‡ |
| Adenosquamous carcinoma | 9 (4.5) | 3 (5.4) | 6 (4.9) | 0 (0) | |
| Squamous carcinoma | 3 (1.5) | 0 (0) | 3 (2.5) | 0 (0) | |
| LCC/NOS | 5 (2.5) | 1 (1.8) | 4 (3.3) | 0 (0) | |
| Methods of obtaining pathological tissue n(%) | |||||
| Lung tumor resection | 100 (50.0) | 24 (42.9) | 65 (53.3) | 11 (50.0) | 0.003§ |
| LN resection | 71 (35.5) | 25 (44.6) | 44 (36.0) | 2 (9.1) | |
| Puncture | 19 (9.5) | 4 (7.1) | 9 (7.4) | 6 (27.3) | |
| Others | 10 (5.0) | 3 (5.4) | 4 (3.3) | 3 (13.6) | |
| Site of pathological tissue n= (%) | |||||
| Lung tumor | 116 (58.0) | 27 (48.2) | 72 (59.0) | 17 (77.3) | 0.217¶ |
| Metastatic LN | 74 (37.0) | 26 (46.4) | 46 (37.7) | 2 (9.1) | |
| Pleura | 4 (2.0) | 1 (1.8) | 1 (0.8) | 2 (9.1) | |
| Other metastases | 6 (3.0) | 2 (3.6) | 3 (2.5) | 1 (4.5) | |
| Pathology-ALK detection interval (month) | |||||
| Median | 7.9 | 7.0 | 7.7 | 18.0 | 0.727 |
| Range | 0.1–118.4 | 0.1–63.3 | 0.1–80.9 | 0.2–118.4 | 0.065†† |
| Pathology-ALK detection interval n= (%) | |||||
| ≤24 | 155 (77.5) | 49 (87.5) | 92 (75.4) | 14 (63.7) | 0.140 |
| >24 ≤48 | 29 (14.5) | 6 (10.7) | 20 (16.4) | 3 (13.6) | 0.020‡‡ |
| >48 | 16 (8.0) | 1 (1.8) | 10 (8.2) | 5 (22.7) | |
Comparison between the positive and negative groups.
Comparison between adenocarcinoma and NAC.
Comparison between lung tumor/LN resection and puncture/others.
Comparison between lung tumor and metastatic LN.
Comparison in time between UN and detectable specimens.
Comparison of the time of ALK detection ≤48 and>48 months between UN, detectable specimens. ALK, anaplastic lymphoma kinase; EML4, echinoderm microtubule-associated protein-like-4; LCC, large cell carcinoma; LN, lymph node; NAC, non-adenocarcinoma; NOS, not otherwise specified; UN, unknown (either the result was uninformative or the section was undetectable).